Elevated hematocrit enhances platelet accumulation following vascular injury

Blood

Volumn 129, Issue 18, 2017, Pages 2537-2546

  Walton, Bethany L ^a   Lehmann, Marcus ^b   Skorczewski, Tyler ^c   Holle, Lori A ^a   Beckman, Joan D ^a   Cribb, Jeremy A ^d   Mooberry, Micah J ^a   Wufsus, Adam R ^b   Cooley, Brian C ^a   Homeister, Jonathan W ^a   Pawlinski, Rafal ^a   Falvo, Michael R ^d   Key, Nigel S ^a   Fogelson, Aaron L ^e,f   Neeves, Keith B ^b,g   Wolberg, Alisa S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Department of Metallurgical and Materials Engineering   (United States)

^c Hospital for Special Surgery   (United States)

^d The University of North Carolina at Chapel Hill   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f University of Utah   (United States)

^g University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; PEPTIDE HYDROLASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SMEAR; CAROTID ARTERY OBSTRUCTION; CELL INTERACTION; COMPUTER MODEL; CONTROLLED STUDY; ERYTHROCYTE COUNT; EX VIVO STUDY; EXPERIMENTAL MODEL; FEMALE; HEMATOCRIT; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR SIZE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; SHEAR RATE; THROMBOCYTE COUNT; ANIMAL; ARTERY; BLOOD VESSEL INJURY; HUMAN; INJURIES; METABOLISM; SHEAR STRENGTH; THROMBOCYTE; THROMBOSIS;

ANIMALS; ANTITHROMBIN III; ARTERIES; BLOOD COAGULATION; BLOOD PLATELETS; FEMALE; HEMATOCRIT; HUMANS; MALE; MICE; PEPTIDE HYDROLASES; SHEAR STRENGTH; THROMBOSIS; VASCULAR SYSTEM INJURIES;

EID: 85018898679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-10-746479     Document Type: Article

References (61)

1. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96(1):168-173.
2. Pries AR, Neuhaus D, Gaehtgens P. Blood viscosity in tube flow: dependence on diameter and hematocrit. Am J Physiol. 1992;263(6 Pt 2):H1770-H1778.
3. Errill EW. Rheology of blood. Physiol Rev. 1969;49(4):863-888.
4. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost. 2003;29(5):451-458.
5. Grabowski EF, Yam K, Gerace M. Evaluation of hemostasis in flowing blood. Am J Hematol. 2012;87(Suppl 1):S51-S55.
6. Fogelson AL, Neeves KB. Fluid mechanics of blood clot formation. Annu Rev Fluid Mech. 2015;47:377-403.
7. Silvain J, Pena A, Cayla G, et al. Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. Eur Heart J. 2010;31(22):2816-2821.
8. Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest. 1991;87(2):571-580.
9. Vallés J, Santos MT, Aznar J, et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: downregulation by aspirin ex vivo. Blood. 2002;99(11):3978-3984.
10. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science. 1980;207(4430):541-543.
11. Kuypers FA, Lewis RA, Hua M, et al. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood. 1996;87(3):1179-1187.
12. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood. 2012;120(18):3837-3845.
13. Peyrou V, Lormeau JC, Hérault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost. 1999;81(3):400-406.
14. Horne MK III, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol. 2006;133(4):403-408.
15. Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem. 2012;58(8):1252-1259.
16. van Beers EJ, Schaap MC, Berckmans RJ, et al; CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica. 2009;94(11):1513-1519.
17. Rubin O, Delobel J, Prudent M, et al. Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion. 2013;53(8):1744-1754.
18. Mooberry MJ, Bradford R, Hobl EL, Lin FC, Jilma B, Key NS. Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. J Thromb Haemost. 2016;14(5):1031-1042.
19. Sorlie PD, Garcia-Palmieri MR, Costas R Jr, Havlik RJ. Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. Am Heart J. 1981;101(4):456-461.
20. Erikssen G, Thaulow E, Sandvik L, Stormorken H, Erikssen J. Haematocrit: a predictor of cardiovascular mortality? J Intern Med. 1993;234(5):493-499.
21. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease - the Framingham study: a 34-year follow-up. Am Heart J. 1994;127(3):674-682.
22. Wannamethee G, Shaper AG, Whincup PH. Ischaemic heart disease: association with haematocrit in the British Regional Heart Study. J Epidemiol Community Health. 1994;48(2):112-118.
23. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111(16):2042-2049.
24. Toss F, Nordström A, Nordström P. Association between hematocrit in late adolescence and subsequent myocardial infarction in Swedish men. Int J Cardiol. 2013;168(4):3588-3593.
25. Paffett-Lugassy N, Hsia N, Fraenkel PG, et al. Functional conservation of erythropoietin signaling in zebrafish. Blood. 2007;110(7):2718-2726.
26. Shibata J, Hasegawa J, Siemens HJ, et al. Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood. 2003;101(11):4416-4422.
27. Lamrani L, Lacout C, Ollivier V, et al. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood. 2014;124(7):1136-1145.
28. Strassel C, Kubovcakova L, Mangin PH, et al. Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost. 2015;113(2):414-425.
29. Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med. 2013;210(2):205-208.
30. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006;70(2):246-250.
31. Choi D, Schroer SA, Lu SY, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med. 2010;207(13):2831-2842.
32. Hand CC, Brines M. Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Invest Med. 2011;59:1073-1082.
33. Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011;117(18):4953-4963.
34. Walton BL, Getz TM, Bergmeier W, Lin F-C, Uitte de Willige S, Wolberg AS. The fibrinogen γA/γ′ isoform does not promote acute arterial thrombosis in mice. J Thromb Haemost. 2014;12(5):680-689.
35. Crowl L, Fogelson AL. Analysis of mechanisms for platelet near-wall excess under arterial blood flow conditions. J Fluid Mech. 2011;676:348-375.
36. Crowl LM, Fogelson AL. Computational model of whole blood exhibiting lateral platelet motion induced by red blood cells. Int J Numer Methods Biomed Eng. 2010;26(3-4):471-487.
37. Skorczewski T, Erickson LC, Fogelson AL. Platelet motion near a vessel wall or thrombus surface in two-dimensional whole blood simulations. Biophys J. 2013;104(8):1764-1772.
38. Rana K, Timmer BJ, Neeves KB. A combined microfluidic-microstencil method for patterning biomolecules and cells. Biomicrofluidics. 2014;8(5):056502.
39. Lehmann M, Wallbank AM, Dennis KA, et al. Onchip recalcification of citrated whole blood using a microfluidic herringbone mixer. Biomicrofluidics. 2015;9(6):064106.
40. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 1996;88(5):1873-1880.
41. Gilson CR, Kraus TS, Hod EA, et al. A novel mouse model of red blood cell storage and posttransfusion in vivo survival. Transfusion. 2009;49(8):1546-1553.
42. Marchioli R, Finazzi G, Specchia G, et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
43. Kumar A, Graham MD. Mechanism of margination in confined flows of blood and other multicomponent suspensions. Phys Rev Lett. 2012;109(10):108102.
44. Reasor DA Jr, Mehrabadi M, Ku DN, Aidun CK. Determination of critical parameters in platelet margination. Ann Biomed Eng. 2013;41(2):238-249.
45. Zhao H, Shaqfeh ES. Shear-induced platelet margination in a microchannel. Phys Rev E Stat Nonlin Soft Matter Phys. 2011;83(6 Pt 1):061924.
46. Vahidkhah K, Diamond SL, Bagchi P. Platelet dynamics in three-dimensional simulation of whole blood. Biophys J. 2014;106(11):2529-2540.
47. Stalker TJ, Welsh JD, Tomaiuolo M, et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood. 2014;124(11):1824-1831.
48. Wang W, Diacovo TG, Chen J, Freund JB, King MR. Simulation of platelet, thrombus and erythrocyte hydrodynamic interactions in a 3D arteriole with in vivo comparison. PLoS One. 2013;8(10):e76949.
49. Landolfi R, Marchioli R, Kutti J, et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124.
50. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-1234.
51. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377-2381.
52. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood. 2001;98(12):3228-3233.
53. Fujita H, Sakuma R, Tomiyama J, et al. Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia vera. Br J Haematol. 2011;152(2):238-240.
54. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993;44(1):63-65.
55. Yasin Z, Witting S, Palascak MB, Joiner CH, Rucknagel DL, Franco RS. Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. Blood. 2003;102(1):365-370.
56. Barr JD, Chauhan AK, Schaeffer GV, Hansen JK, Motto DG. Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood. 2013;121(18):3733-3741.
57. Ciciliano JC, Sakurai Y, Myers DR, et al. Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. Blood. 2015;126(6):817-824.
58. Woollard KJ, Sturgeon S, Chin-Dusting JP, Salem HH, Jackson SP. Erythrocyte hemolysis and hemoglobin oxidation promote ferric chloride-induced vascular injury. J Biol Chem. 2009;284(19):13110-13118.
59. Schoenwaelder SM, Jackson SP. Ferric chloride thrombosis model: unraveling the vascular effects of a highly corrosive oxidant. Blood. 2015;126(24):2652-2653.
60. Neeves KB. Physiochemical artifacts in FeCl3 thrombosis models. Blood. 2015;126(6):700-701.
61. Jensen AS, Johansson PI, Idorn L, et al. The haematocrit-an important factor causing impaired haemostasis in patients with cyanotic congenital heart disease. Int J Cardiol. 2013;167(4):1317-1321.